Content

Ipamorelin Benefits, Side Effects, Legal Status

Creator: Nadia Okonjo, Health Writer
Published: 2026-08-14

Developed at Novo Nordisk in the late 1990s, ipamorelin is a five-amino-acid peptide that released growth hormone in animal studies without raising cortisol even at more than 200 times its effective dose.

Nadia Okonjo, Health Writer August 14, 2026 8 min read

A woman in a long-sleeve top doing a seated stretch on a mat in a bright home studio

The short version

Ipamorelin is a synthetic pentapeptide that mimics the hormone ghrelin at the GHS-R1a receptor, prompting the pituitary to release growth hormone in pulses that resemble natural secretion.
Its defining feature is selectivity: in the 1998 animal studies that introduced it, ipamorelin caused no significant ACTH or cortisol release even at more than 200 times the effective GH dose.
Human trial evidence is thin: two phase 2 trials in postoperative ileus found ipamorelin well tolerated but no better than placebo, and development ended. Trials for recovery, body-composition, or sleep uses were never completed.
Reported side effects — injection-site reactions, headache, flushing, water retention — are mostly class-effect observations; the best controlled tolerability data come from the surgical trials.
Ipamorelin was never scheduled or criminalized, and it is not FDA-approved for any use. After a 2023–2024 arc through FDA's compounding lists and an advisory-committee vote, a licensed provider may still prescribe compounded preparations where appropriate.
WADA prohibits all growth hormone secretagogues, ipamorelin included, at all times — relevant only if you compete in tested sport.

Every list of ipamorelin benefits traces back to a laboratory problem from the 1990s. The first growth hormone-releasing peptides — GHRP-6, then GHRP-2 — could reliably trigger growth hormone (GH) release from the pituitary, but messily: both nudged the stress hormones ACTH and cortisol upward, and GHRP-6 also stimulated appetite. In the late 1990s, scientists at Novo Nordisk built a five-amino-acid peptide derived from GHRP-1 and tested it against exactly those flaws. When Raun and colleagues published the results in 1998, they called ipamorelin "the first selective growth hormone secretagogue": in animal models, it released GH about as potently as GHRP-6, yet produced no significant ACTH or cortisol release even at doses more than 200-fold the effective GH dose — and without GHRP-6's appetite stimulation. Nearly everything people hope for from ipamorelin — recovery, body composition, sleep-adjacent effects — starts from that one property: growth hormone release with less hormonal noise.

How ipamorelin works

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as an agonist at GHS-R1a — the growth hormone secretagogue receptor, better known as the ghrelin receptor — on the somatotroph cells of the pituitary gland. By mimicking ghrelin there, it prompts the pituitary to release a pulse of growth hormone — and two details of that mechanism matter for patients.

First, the release is pulsatile. Ipamorelin does not add growth hormone from outside; it asks the pituitary to secrete its own, in bursts that mirror natural secretion, leaving the body's feedback loops intact — somatostatin, the brake on GH release, and IGF-I, the liver hormone that carries much of GH's downstream signal. Like other GHRPs, it also works partly by functionally reducing somatostatin's braking effect, amplifying each pulse. Direct growth hormone injections, by contrast, create continuous exposure that bypasses those controls.

Second, the release is selective — the Raun 1998 finding that GH came without the ACTH, cortisol, and appetite effects of GHRP-6 and GHRP-2, in animal models, which is where that claim lives. One caveat: in a later rat study, ipamorelin-treated animals did gain body weight dose-dependently, so "appetite-neutral" is softer in practice than the discovery paper's framing suggests.

Ipamorelin is one of two peptide classes that raise GH through the pituitary; the other — GHRH analogs such as sermorelin, CJC-1295, and tesamorelin — works through the separate GHRH receptor, and the two are often paired in combination products. If your questions are mostly about the combination, the deep dive lives in our CJC-1295 and ipamorelin article.

Ipamorelin benefits: what studies measured

No ipamorelin benefit has been confirmed in a completed human wellness trial — the evidence base is animal research plus two human surgical trials, and it is worth knowing exactly what each found, in whom.

Bone, in rats. In adult female rats given 0, 18, 90, or 450 µg per day subcutaneously for 15 days, ipamorelin dose-dependently increased longitudinal bone growth from about 42 to 52 µm per day (Johansen 1999) — while, notably, IGF-I and bone markers did not change significantly. In a separate model, adult rats given glucocorticoids (which suppress bone formation) plus ipamorelin at 100 µg/kg three times daily for three months showed a roughly 4-fold higher periosteal bone-formation rate than rats on glucocorticoids alone, along with better muscle strength (Andersen 2001).

Gastric motility, in rats. In a rodent model of postoperative ileus — the gut slowdown that follows abdominal surgery — ipamorelin at 0.014 µmol/kg IV accelerated gastric emptying: 52% of a test meal remained in the stomach versus 78% with vehicle (Greenwood-Van Meerveld 2012).

Postoperative ileus, in humans — the trials that ended development. The rodent motility signal led to a clinical program. In a published phase 2 trial of 114 bowel-resection patients, ipamorelin at 0.03 mg/kg IV twice daily was well tolerated — adverse-event rates were 87.5% in the ipamorelin group versus 94.8% on placebo — but it missed its primary endpoint: median time to first tolerated meal was 25.3 hours versus 32.6 hours on placebo, p=0.15 (Beck 2014). A separate, larger phase 2 dose-finding trial of roughly 320 patients (NCT01280344) was also negative. Development for that use ended there.

Everything else. For the uses patients ask about — recovery, body composition, sleep, healthy aging — human studies never progressed far enough to confirm anything. What exists is GH physiology: growth hormone participates in tissue repair, body-composition regulation, and slow-wave sleep, and ipamorelin raises GH in a pattern that preserves natural pulsing. Whether that translates into meaningful outcomes is the question the human evidence has not answered.

How ipamorelin compares with other secretagogues

The practical differences come down to receptor, selectivity, and what else gets released along with growth hormone.

Compound	Receptor	Selectivity for GH	Appetite effect	ACTH/cortisol effect
Ipamorelin	GHS-R1a (ghrelin receptor)	High — "the first selective GH secretagogue" (Raun 1998)	No strong stimulation reported; rats on multi-week courses did gain weight	No significant release even at >200× the effective GH dose (animal data)
GHRP-6	GHS-R1a	Lower	Strong appetite stimulation	Raises both
GHRP-2	GHS-R1a	Lower	Milder than GHRP-6	Raises both
Sermorelin-class GHRH analogs (sermorelin, CJC-1295, tesamorelin)	GHRH receptor	GH-directed by mechanism	Not characteristic	Not characteristic

Sermorelin and its relatives are analogs of growth hormone-releasing hormone — the brain's own "release GH" signal — acting on a different receptor; our sermorelin vs HGH article covers how that class compares with direct growth hormone therapy. Because the two pathways are complementary, prescribers who want both signals often use a combination product — which is where a formulation pairing tesamorelin with ipamorelin fits.

Side effects and who should be cautious

The side effects most often attributed to ipamorelin are injection-site reactions (redness, swelling, mild discomfort), headache, flushing or a feeling of warmth, and mild water retention. A label belongs on that list: most of those frequency claims are uncited observations extrapolated from the GH-peptide class, not published trial statistics. The best controlled tolerability data come from the postoperative-ileus trials, where adverse-event rates in 114 surgical patients were slightly lower with ipamorelin (87.5%) than with placebo (94.8%) — reassuring, but measured in an IV hospital setting, not long-term outpatient use.

Rarer flags deserve more respect than the common ones:

Blood-glucose changes. Growth hormone counter-regulates insulin, and glucose shifts have been observed with GH-raising compounds — a particular consideration for anyone with insulin resistance or diabetes.
Joint aches and carpal-tunnel-type symptoms. These are classically associated with supraphysiologic GH exposure; they are less expected at secretagogue-level elevations but belong on the watch list.
Cardiovascular caution. Potential effects on heart rate and blood pressure have been raised, including in FDA's stated concerns during the compounding review; anyone with heart disease needs individual medical judgment.

There is also a recognized caution set: active cancer or a history of malignancy (growth hormone's role in cell proliferation is a theoretical concern), pregnancy or nursing, pediatric use, uncontrolled diabetes, severe cardiovascular disease, active diabetic retinopathy, and medications that affect glucose, blood pressure, or endocrine function. That list is exactly what a prescribing provider screens for, with your chart in front of them. Long-term human safety data, said plainly, do not exist.

The legal status of ipamorelin

Ipamorelin has never been scheduled or criminalized in the United States, and it is not FDA-approved for any use — the "banned" impression lives in the gap between those two facts. The chronology is short and specific:

October 2023. FDA placed ipamorelin in Category 2 of its interim list of bulk drug substances under section 503A — the category for substances with identified safety concerns — which effectively paused pharmacy compounding of it.
September 2024. FDA announced on September 20 (effective September 27) the removal of five substances, ipamorelin among them, from Category 2. The removal happened because the original nominators withdrew their nominations — not because FDA reversed its assessment — and it cleared the way for referral to the Pharmacy Compounding Advisory Committee (PCAC).
October 29, 2024. At its meeting, PCAC voted against adding ipamorelin to the 503A bulks list, consistent with FDA's own briefing recommendation. The committee is advisory; formal rulemaking is still pending.

A licensed provider may still prescribe — that decision is between you and your doctor. FDA review status describes where a substance stands in a regulatory process; it is not a criminal statute, and an advisory vote is not a prescribing ban.

One separate rulebook applies only to competitive athletes: the World Anti-Doping Agency's Prohibited List bans all growth hormone secretagogues, ipamorelin included, at all times — in and out of competition — under class S2. If you are tested, a prescription does not exempt you; if you are not a tested athlete, the list has no bearing on you.

Fitting ipamorelin into a plan

Ipamorelin's appeal is easy to state: growth-hormone support with less hormonal noise than the peptides that came before it. The evidence behind that appeal is real but bounded — consistent animal data, a clean tolerability record in surgical trials, and no completed human trials for the uses most patients care about. A profile like that calls for individual medical judgment, not a general recommendation. Through Promise, ipamorelin-containing formulations are available only by prescription: a licensed provider reviews every request against your health history — not everyone qualifies, and a provider may decline. If a provider does prescribe, the medication is compounded — prepared for an individual patient by a licensed U.S. compounding pharmacy — and every detail of the protocol, including dose, is set by that provider.

This article is educational and is not medical advice. Talk with a licensed clinician about your specific situation.

Common questions

What does ipamorelin do on its own?

On its own, ipamorelin signals the pituitary to release growth hormone in pulses by mimicking ghrelin at the GHS-R1a receptor — without the cortisol, ACTH, and appetite effects of the older peptides in its family, per the animal studies that defined it. What that produces in a given person is individual, and human trials for wellness uses were never completed.

What are the most common side effects of ipamorelin?

The most commonly reported are injection-site redness or swelling, headache, flushing, and mild water retention — frequencies drawn largely from class-effect observation rather than controlled trials. Rarer concerns include blood-glucose changes, joint or carpal-tunnel-type symptoms, and cardiovascular effects, which is part of what a prescribing provider screens and monitors for.

Is ipamorelin FDA-approved?

No. Ipamorelin is not FDA-approved for any use and never has been. Where it is available by prescription, it is prepared as a compounded medication, which is different from an FDA-approved product.

Why do people say ipamorelin is banned?

Because of a compounding-rule chapter, not a ban. FDA placed ipamorelin in Category 2 of its interim 503A bulk-substances list in October 2023, pausing pharmacy compounding; removed it in September 2024 — because the original nominators withdrew their nominations, not because FDA changed its mind — and in October 2024 its advisory committee voted against adding it to the compounding list. None of that scheduled or criminalized ipamorelin, and the prescribing decision still belongs to a licensed provider and their patient.

Did ipamorelin pass clinical trials?

No — it reached phase 2 and stopped. In the published trial of 114 bowel-resection patients, ipamorelin was well tolerated but missed its primary endpoint (median 25.3 hours to first tolerated meal versus 32.6 hours on placebo, p=0.15), and a larger dose-finding trial of roughly 320 patients was also negative. Development for postoperative ileus ended. A halted program is not a prescribing ban — but it does mean the human efficacy evidence never arrived.

Is ipamorelin prohibited for athletes?

Yes, for tested athletes. WADA prohibits all growth hormone secretagogues, ipamorelin included, at all times — in and out of competition — under class S2 of the Prohibited List. A medical prescription does not create an exemption from anti-doping rules.

What is the difference between ipamorelin and sermorelin?

They work on different receptors. Sermorelin is an analog of growth hormone-releasing hormone and acts on the GHRH receptor; ipamorelin mimics ghrelin at the GHS-R1a receptor. Both aim to raise the body's own growth hormone in pulses rather than replacing it, and because the pathways are complementary, the two classes are sometimes combined in a single prescription formulation.

Why is there no ipamorelin dosage chart?

Because no validated human dose exists for the uses people search for. The only rigorously dosed human studies used 0.03 mg/kg IV twice daily in hospitalized surgical patients — a setting that says nothing about outpatient subcutaneous use. Numbers circulating online come from community practice, not clinical validation, and we publish none of them. A prescribing provider sets any protocol individually, for the patient in front of them.